Description

Bismuth drugs, despite being clinically used for decades, surprisingly remain in use and effective for the treatment of Helicobacter pylori infection, even for resistant strains when co-administrated with antibiotics. However,

Bismuth drugs, despite being clinically used for decades, surprisingly remain in use and effective for the treatment of Helicobacter pylori infection, even for resistant strains when co-administrated with antibiotics. However, the molecular mechanisms underlying the clinically sustained susceptibility of H. pylori to bismuth drugs remain elusive.

Reuse Permissions
  • application/pdf

    Download count: 0

    Details

    Contributors
    Date Created
    • 2017-04-19
    Resource Type
  • Text
  • Collections this item is in
    Identifier
    • Digital object identifier: 10.1039/C7SC00766C
    • Identifier Type
      International standard serial number
      Identifier Value
      2041-6520
    • Identifier Type
      International standard serial number
      Identifier Value
      2041-6539
    Note

    Citation and reuse

    Cite this item

    This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.

    Wang, Y., Hu, L., Xu, F., Quan, Q., Lai, Y., Xia, W., . . . Sun, H. (2017). Integrative approach for the analysis of the proteome-wide response to bismuth drugs in Helicobacter pylori. Chem. Sci., 8(6), 4626-4633. doi:10.1039/c7sc00766c

    Machine-readable links